Cardio Diagnostics Holdings Past Earnings Performance
Past criteria checks 0/6
Cardio Diagnostics Holdings's earnings have been declining at an average annual rate of -82.7%, while the Biotechs industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 120.4% per year.
Key information
-82.7%
Earnings growth rate
-32.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 120.4% |
| Return on equity | -283.2% |
| Net Margin | -49,087.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Cardio Diagnostics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -8 | 7 | 0 |
| 30 Sep 23 | 0 | -9 | 8 | 0 |
| 30 Jun 23 | 0 | -9 | 8 | 0 |
| 31 Mar 23 | 0 | -5 | 6 | 0 |
| 31 Dec 22 | 0 | -5 | 4 | 0 |
| 30 Sep 22 | 0 | -2 | 2 | 0 |
| 30 Jun 22 | 0 | -2 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -1 | 1 | 0 |
Quality Earnings: CDIO is currently unprofitable.
Growing Profit Margin: CDIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CDIO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CDIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: CDIO has a negative Return on Equity (-283.18%), as it is currently unprofitable.